Emerging Trends in Oncology: ASCO 2024 Highlights Next-Gen Antibody-Drug Conjugates and More
ONCYOncolytics Biotech (ONCY) Prnewswire·2024-05-25 00:16

USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, May 24, 2024 /PRNewswire/ -- USA News Group News Commentary – As the 2024 American Society of Clinical Oncology (ASCO) annual meeting approaches, excitement builds over the latest in cancer treatment advancements, particularly in Antibody-Drug Conjugates (ADCs). From May 31 to June 4, industry leaders will unveil new data on late-stage and approved therapies. Recent FDA approvals are also enriching the treatment landsc ...